With Sharp Drop in Demand, Community-Based COVID-19 Testing Sites to End Operations March 31

The Illinois Department of Public Health (IDPH) announced today that in response to a sharp drop in the demand for COVID-19 testing services at the ten Community-Based Testing Sites and the anticipated end of federal funding, operations at the locations will end on March 31. IDPH previewed that operations would be winding down when the mask mandate was lifted and has seen traffic at the sites – which carried out more than 1.5 million tests in total throughout their operation – drop precipitously in recent weeks. The sites are currently handling less than one percent of the tests being conducted statewide.

2022-03-28T10:20:03-05:00March 28, 2022|

Illinois Department of Public Health Adds New COVID-19 Treatment for Distribution Across Illinois

As a new COVID-19 treatment rolls out across the country, the Illinois Department of Public Health (IDPH) continues to distribute these life-saving therapeutics equitably across the state.  On February 11, 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for a new monoclonal antibody, bebtelovimab, for the treatment of COVID-19. 

2022-02-23T10:52:17-06:00February 23, 2022|

Gov. Pritzker Announces Illinois Plan to Lift Statewide Indoor Mask Requirement on Monday, February 28

With statewide COVID-19 hospitalization rates declining faster than any other point in the pandemic, Illinois is on track to lift the statewide indoor mask requirement on Monday, February 28, 2022. Mask requirements will continue where federally mandated, such as on public transit and in high-risk settings including healthcare facilities and congregate care.

2022-02-14T14:50:12-06:00February 14, 2022|

Illinois Department of Public Health Announces COVID-19 Antivirals Available in the Coming Weeks

The Illinois Department of Public Health (IDPH) is announcing two new COVID-19 oral antivirals, Paxlovid (Pfizer) and Molnupiravir (Merck), will be available in Illinois later this month. The antivirals are for those with mild-to-moderate COVID-19 who are at high risk for becoming severely ill, including hospitalization or death.

2022-01-19T17:21:42-06:00January 18, 2022|

CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children

Today, CDC is updating our recommendation for when many people can receive a booster shot, shortening the interval from 6 months to 5 months for people who received the Pfizer-BioNTech COVID-19 Vaccine. This means that people can now receive an mRNA booster shot 5 months after completing their Pfizer-BioNTech primary series. The booster interval recommendation for people who received the J&J vaccine (2 months) or the Moderna vaccine (6 months), has not changed.

2022-01-19T17:26:23-06:00January 4, 2022|
Go to Top